ExSAR Corporation names Pedro Huertas, MD, PhD, as Chief Medical Officer responsible for overseeing the clinical strategy and development of the Company’s programs associated with orally available drugs for treatment of diseases of misfolded proteins.

Dr. Huertas received a Doctor of Medicine degree from Harvard Medical School/Massachusetts Institute of Technology where he was awarded the Becton Dickinson Research Scholarship and James H. Robinson Memorial Prize in Surgery. He completed his Doctor of Philosophy in Cell and Developmental Biology from Harvard University and also holds a Masters in Business Administration from MIT’s Sloan School of Management. Dr. Huertas is the Medical Director of the Benson Henry Institute at Massachusetts General Hospital, and holds appointments at MGH, McLean Hospital, Harvard Medical School and MIT.

Most recently, Dr. Huertas was the Chief Development and Strategy Officer at Amicus Therapeutics, Inc, a venture-financed biopharmaceutical company developing pharmacological chaperones for diseases of conformation. Prior to joining Amicus, Dr. Huertas was Chief Medical Officer (Acting) at StemCells, Inc. (NASDAQ: STEM), Chief Medical Officer at Novazyme, Inc., a venture-financed R&D company, and Director of Strategic Development and Medical Director at Genzyme, Inc. (NASDAQ: GENZ).

In addition, Dr. Huertas has served as an expert advisor to venture capital firms, governmental and non-governmental agencies on issues related to biotechnology and uses of biological resources as means of sustainable economic development. Dr. Huertas sits on the Sloan Fellows’ Board of Governors at the Sloan School of Management at MIT, Advisory Board of the Division of Health Sciences and Technology at Harvard Medical School and MIT, the Advisory Board of the Biomedical Entrepreneurship Program (BEP) at the Sloan School of Management at MIT, and the Advisory Board of the Program on Depression of the Massachusetts General Hospital and Harvard Medical School.

Bijan Almassian, PhD, Chief Executive Officer of ExSAR commented, "Dr. Huertas brings an exceptional combination of scientific excellence and proven drug development to ExSAR, and we are fortunate to have him join us at this very important juncture in our Company’s development. His experience will be an important asset to the Company as we accelerate our efforts to develop and commercialize our products."

Dr. Huertas said, "I believe that ExSAR is poised uniquely to capture the value of molecular guides to treat diseases of conformation, some of the cruelest disease affecting humans."

About ExSAR Corporation
ExSAR is a biotechnology company focused on developing orally available small drug molecules for the treatment of protein misfolding disorders.

ExSAR utilizes their proprietary drug discovery technology (H/D-Ex) based on hydrogen/deuterium exchange mass spectrometry to validate candidate compounds for in-licensing and development.

ExSAR also provides H/D-Ex on a contractual basis to academic laboratories and pharmaceutical companies for protein target-ligand screening and epitope mapping applications.

 

Press Releases | Presentations & Conferences | Publications | Media Coverage | Links